SPY339.39-6.39 -1.85%
DIA277.00-6.34 -2.24%
IXIC11,358.94-189.35 -1.64%

Moderna Announces Updates on Respiratory Syncytial Virus Vaccine Program

Moderna regains rights to adult RSV vaccine program from Merck Start of Phase 1 dosing for mRNA-1345, Moderna’s vaccine candidate against RSV  Moderna has consolidated all rights to its prophylactic

· 10/08/2020 06:49

Moderna regains rights to adult RSV vaccine program from Merck

Start of Phase 1 dosing for mRNA-1345, Moderna’s vaccine candidate against RSV 

Moderna has consolidated all rights to its prophylactic vaccines portfolio

Conference call to be held on Thursday, October 8 at 8:00 a.m. ET